The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Swiss Biotech Report 2026: Strong performance with new records in revenues and investments in privately funded companies

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

Fraud campaigns without connection to the Swiss Biotech Association or the Swiss Biotech Day

We are tracking and escalating fraud campaigns targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

SOTIO: FDA Orphan Drug Designation for a potential antibody-drug conjugate for Sarcoma

First-in-human study of SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma, reinforcing its potential as a
June 3, 2026

Volv Global: Machine learning maps and discovers clinical endpoints in Pompe disease

In the largest machine learning study of Pompe disease to date, Volv Global demonstrates that clinician-defined endpoints can be tracked and novel disease features discovered in US claims data across 3,549 patients
June 1, 2026

leadXpro and Arzanya collaborate on exploring macrocycle discovery on membrane proteins

Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets.
May 29, 2026

LimmaTech Biologics to be acquired by Lilly

LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly. LimmaTech’s self-adjuvating and multi-antigen vaccine platform addresses common bacterial infections that currently cannot be prevented Lead program focuses on Staphylococcus aureus infection
May 26, 2026